49ers' visit gives Packers a chance to damage the playoff hopes of their postseason nemesis

WASHINGTON — A ninth US telecommunications firm was confirmed to have been hacked as part of a massive Chinese espionage operation that gave officials in Beijing access to private text messages and phone conversations of an unknown number of Americans, a top White House official said Friday. Biden administration officials said this month that at least eight telecommunications companies, as well as dozens of nations, had been affected by the Chinese hacking blitz known as Salt Typhoon. Register to read this story and more for free . Signing up for an account helps us improve your browsing experience. OR See our subscription options.

PORT HARCOURT – The Managing Director of the Niger Delta Development Commission, NDDC, Dr Samuel Ogbuku, says the Commission is investing in digital learning because it holds the key to unlocking untapped potential and shaping the future of the Niger Delta region. Ogbuku, who spoke during an interactive session with newsmen at the NDDC’s headquarters in Port Harcourt, stated that the Commission was determined to harness the power of technology to build a brighter future for the Niger Delta, where every child would have the tools and opportunities to succeed. He remarked that the NDDC, in collaboration with the Renewed Hope Initiative, RHI, of Nigeria’s First Lady, Sen. Oluremi Tinubu, launched a large-scale digital education initiative aimed at distributing 45,000 U-Lesson tablets to primary and secondary schools across the nine states in Nigeria’s Niger Delta region. According to the NDDC boss, the initiative was aimed at enhancing educational opportunities in the Niger Delta region through the distribution of U-Lesson tablets and software designed to improve student literacy and learning outcomes. He stated: “The initiative fosters a conducive learning environment by integrating digital learning resources. It aligns with the Sustainable Development Goals, particularly Goal 4, which emphasises the importance of inclusive and equitable quality education. This approach aims to empower students, ensuring they have the tools to excel academically and compete globally. “It is all about being pragmatic and positioning our region for the future. Digital education came to the forefront during the outbreak of the Coronavirus pandemic, COVID-19. The pandemic taught us that interpersonal learning will be a thing of the past very soon. During the COVID-19 period, churches were functioning through online platforms. “We want the children growing up to be able to use computers and other digital devices for learning. We realise that some of our students sent outside the country for postgraduate studies struggle with the highly computerised modern society. That is why we are investing more in educating our students on digital learning.” “Education is improving, and even our phones are always on software upgrades. Education is also being improved to meet the present reality of our society so that students can compete with others when they leave our country.” Ogbuku in a statement signed by Seledi Thompson-Wakama, Director Corporate Affairs, NDDC on Sunday, explained that the U-Lesson software was tailored to the Nigerian educational framework, noting that it featured an offline video library, allowing students to access educational content without internet connectivity. The Managing Director stated: “This digital tool complements traditional face-to-face instruction, empowering students to master their materials and excel in tests and examinations. We believe that every student in our region deserves a quality education, and we are committed to providing the resources necessary to make this a reality.” Speaking on the NDDC Foreign Post-Graduate Scholarship Programme, Ogbuku observed that 2,700 students from the Niger Delta had benefitted from the scheme since its inception in 2010. He noted: “We reactivated and strengthened our foreign postgraduate scholarship scheme, making it more merit-based and funding it adequately to prevent the challenges of the past.” He said: “We have made educational development and human capacity building our key policy thrust. The previous negative narrative of the NDDC is changing due to the conscious and sustained efforts to chart a new course of development for the region.Crown Royal Paints Nashville Purple During "The 58th Annual CMA Awards" Week from launch of Crown Royal 31 Year Old in Partnership with Daniel Diamond to Generous Moment on CMA Awards Stage Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Top trending stories from the past week. News, Sports, and more throughout the week. The week's obituaries, delivered to your inbox.Can the Canucks survive Quinn Hughes' 'week-to-week' injury?

CENTURION: South Africa tailenders Kagiso Rabada and Marco Jansen hung in against relentless fast bowler Mohammad Abbas for a tense two-wicket win in the first test on Sunday to seal the Proteas' place in next year's World Test Championship final. Jansen (16 not out) overshadowed Abbas' brilliant figures of 6-54 with a square driven boundary against the fast bowler as South Africa reached 150-8 just after lunch on Day 4 and escaped with a close win in the opener of the two-match series. “Quite an emotional moment for me, good advert for test cricket,” said South Africa captain Temba Bavuma, who made 40. “We haven't been ruthless but have found a way to ensure the result was on our side. Lot of joy and happiness on our side, a bit of a rollercoaster, glad that we were able to get the result.” Abbas, making a comeback after more than three years in the test wilderness, had knocked back South Africa's tricky chase of 148 runs in a marathon 13-over spell before lunch on Day 4 as the home team limped to 99-8, losing four wickets for three runs. However, Rabada changed gears in an unbroken 51-run stand with Jansen and made an unbeaten 31 off 26 balls with five fours to seal a memorable victory and denied Pakistan its first test win in South Africa in almost 18 years. South Africa had started this WTC cycle with a 1-1 drawn series against India before getting swept 2-0 in New Zealand. But since then the Proteas have beaten West Indies, Bangladesh and Sri Lanka to stay on top of the table. “It (WTC final) is a big one, not just for myself but also the team and the coach," Bavuma said. "The way we started our campaign, against India and then New Zealand with a not-so-strong team, and the way we have gone through with our performances, not many gave us a chance.” India, Australia and Sri Lanka are the other teams still in contention for next June's WTC final against South Africa at Lord's. Captain Temba Bavuma (40) and Aiden Markram (37) had thwarted Abbas for an hour after South Africa resumed at a wobbly 27-3, still needing 121 for victory. Bavuma's controversial dismissal punctuated a South Africa collapse in the latter half of first session with Abbas grabbing three off his six balls in a sensational home team collapse. Bavuma, who made 40, surprisingly didn't request a television review when replays suggested that Abbas' ball had brushed the batter's pocket and didn't make contact with the inside edge of the bat but the South African skipper walked back to the dressing room. Abbas bowled an unchanged marathon spell of 13 overs, but had to wait as Markram and Bavuma saw off eight overs from the fast bowlers. Resuming at 27-3, Bavuma and Markram showed plenty of patience against Abbas' probing line and length before the fast bowler finally got the breakthrough after the first drinks break. Abbas was rewarded for his brilliant seam bowling when he beat the outside edge of Markram's bat and knocked back the off stump. Bavuma survived a couple of close chances when he successfully overturned an on-field lbw decision against him early in the day and Naseem Shah couldn't hold onto a sharp catch at fine leg as he overstepped the boundary cushion while grabbing the ball over his head. South Africa had controlled the game at 96-4 before Bavuma's dismissal saw Abbas finding the outside edges of David Bedingham (14) and Corbin Bosch's (0) bat off successive deliveries and in between Kyle Verreynne dragged Naseem Shah's delivery back onto his stumps. Abbas found the outside edge of Rabada's bat in his first over after lunch that fell just short of wicketkeeper Rizwan before both tailenders took the team home. “Extremely proud of the efforts, but going forward we need to be ruthless,” Pakistan captain Shan Masood said. “We keep making the same mistakes but we have to get over the line, seize moments.” The second test begins at Cape Town on Friday.

The Maricopa County Republican Committee sued to challenge the passage of a voter-approved measure to fund transportation in the Phoenix metropolitan area. The lawsuit suggests that because the ballot measure only received 59.82% of the vote, it should not become law because the Arizona voters in 2022 amended the state’s constitution to require tax proposals to reach a 60% threshold. Proposition 479 asked Maricopa County voters to continue a half-cent sales tax for the next 20 years. The tax was first approved by voters in 1985 and again in 2004. This tax provides revenue for the regional transportation plan approved by mayors across the county, accounting for $14.9 billion, or half, of the $28.2 billion plan . Bryan Blehm, an attorney for the group, argued that the referendum should be decertified because it fell short. He believes this referendum was a new tax, not an old tax, which would require it to reach the 60% threshold. Connect Maricopa, the campaign committee supporting the transportation initiative, filed a motion to intervene Wednesday. On Thursday, the county asked the courts to dismiss the lawsuit entirely. Phoenix Mayor Kate Gallego, a Democrat, called the lawsuit “deeply flawed.” “Maricopa County voters overwhelmingly passed Prop. 479 because they understand that a strong transportation system isn’t political,” she said. “It's critical to our future. This lawsuit is deeply flawed and misguided, and I hope the courts recognize its malignant intentions.” CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER In the breakdown of the measure, 40.5% of the tax revenue is set to fund freeways, 33.5% would fund bus transit and bus rapid transit, 22.5% would go to major roadways and regional transportation infrastructure, and 3.5% would go to light rail maintenance. Gov. Katie Hobbs (D-AZ) released a statement on the lawsuit, saying the proposition will “help create hundreds of thousands of jobs, attract billions of dollars in investment, and continue driving Arizona’s economic momentum forward.”Now 36, she already has a World Cup title and won an Olympic gold medal this year in France. She considered the mental, physical and emotional toll of a new cycle and decided it was time to step away . “Honestly, I think I’ve been somebody that has given everything I’ve had to this team. I don’t do anything halfway. It’s kind of, if you can give 100% to it, then keep going," she said. “With that in mind, I kind of just felt like this was the right time coming off of the Olympics, having the year that we had, entering into a new cycle, a new stage for this team.” Naeher is the latest veteran to announce she's stepping down from the national team as the next generation takes over under coach Emma Hayes. Among those who have wrapped up their soccer careers in the past couple of years include World Cup winners Megan Rapinoe, Alex Morgan, Kelley O'Hara and Ali Krieger. Naeher will be with the team for two more matches in the coming week. The Americans play England at Wembley Stadium on Saturday and then the Netherlands in The Hague on Tuesday. Naeher said she's excited about the next generation of goalkeepers. In addition to Naeher, Mandy Haught of the Utah Royals and Phallon Tullis-Joyce of Manchester United are on the roster for the upcoming matches. Other goalkeepers who have been on recent rosters include Casey Murphy and Jane Campbell. “I think the beauty of goalkeeping is that it’s not really a one-size-fits-all kind of position," she said. "The more that you can understand — that's going to be the challenge any young goalkeeper coming up, is really taking the time to understand what your strengths are and make them really, really elite and separate yourself.” Naeher spoke on Wednesday from London after announcing her retirement on social media Monday . Naeher made her senior debut with the national team in 2014 and was a backup to Hope Solo at the 2015 World Cup, which the United States won. She became the team’s regular starter following the 2016 Rio de Janeiro Olympics and was on the squad that repeated as World Cup winners in 2019. Naeher won a bronze medal at the Tokyo Olympics in 2021 before the U.S. earned gold this year in Paris. She made a key one-handed save in stoppage time to preserve the Americans’ 1-0 victory over Brazil in the Olympic final. For her career, Naeher has appeared 113 games with 110 starts, 88 wins and 68 shutouts. She had four shutouts over the course of the Olympic tournament in France. While she's leaving the national team, she'll play one more year for her club team, the Chicago Red Stars in the National Women's Soccer League. “I hope that I can be remembered as a good teammate, as a competitor, as somebody that was looked on as someone that could be relied upon on the field and supported those players around me,” she said. “I think it’s just been a really special team to be a part of. And I’m very proud of what we have been able to accomplish over the years.” AP soccer: https://apnews.com/hub/soccer

CROWN ROYAL JOINS FORCES WITH NATE SMITH AND SCOTTY HASTING TO SUPPORT VETERANS AS THE AWARD-WINNING WHISKY DONATES $50,000 TO CREATIVETS ON COUNTRY MUSIC'S BIGGEST NIGHT

WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. “The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities,” said Craig Fraser, Chairman and CEO. “With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements,” Mr. Fraser added. “Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization.” Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company’s Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company’s common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient’s condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, “Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF).” The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q (“Form 10-Q”) for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company’s Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company’s product candidates, if approved; the Company’s ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.comManchester City 3 Feyenoord 3 - Defensive disarray, expectations lowered, glimpses from Gundogan